Citadel Advisors’s Entera Bio ENTX Stock Holding History
Bought
Maintained
Sold
Other funds holding ENTX
KCM
PHP
SFCM
XT
SSA
SEIA
Citadel Advisors's ENTX Position: Q1 2026 in Review
Citadel Advisors increased its Entera Bio (ENTX) stake by 510% in Q1 2026, buying an estimated $288K and bringing the position to 245,577 shares worth $273K. The position accounts for ﹤0.01% of the portfolio, ranked #10688.
Citadel Advisors first reported a position in ENTX in Q3 2020 and has held it in 15 quarters since. The position peaked at $402K in Q2 2021. 26 funds tracked by Wall St. Rank hold ENTX as of Q1 2026.
- Citadel Advisors held 245,577 shares of Entera Bio worth $273K as of Q1 2026.
- Citadel Advisors bought 205,347 Entera Bio shares in Q1 2026, an estimated $288K.
- Entera Bio made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #10688 holding.
- Citadel Advisors first reported a position in Entera Bio in Q3 2020 and has held it in 15 quarters since.
- Citadel Advisors's Entera Bio position peaked at $402K in Q2 2021.
- 26 funds tracked by Wall St. Rank held Entera Bio as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.